Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA

被引：73
作者：
Wyatt, LS
Whitehead, SS
Venanzi, KA
Murphy, BR
Moss, B
机构：
[1] NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA
[2] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA
来源：
VACCINE | 1999年 / 18卷 / 5-6期
关键词：
respiratory syncytial virus; vaccinia virus; MVA strain;
D O I：
10.1016/S0264-410X(99)00257-1
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Intranasal and intramuscular immunizations of mice with the highly attenuated MVA strain of vaccinia virus expressing the respiratory syncytial virus (RSV) F or G glycoprotein induced higher RSV antibody titers than those achieved by infection with RSV and greatly restricted the replication of RS challenge virus in both the upper and lower respiratory tracts. In addition, a recombinant MVA expressing both RSV F and G was stable and was as immunogenic as a combination of two single recombinant viruses. The levels of antibodies to RSV F and G, induced by previous intranasal infection with attenuated RSV, were boosted by intramuscular immunization with recombinant MVA. These data support further development of recombinant MVA as a RSV vaccine. (C) 1999 Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码：392 / 397
页数：6
相关论文
共 33 条
[1]   The complete genomic sequence of the modified vaccinia Ankara strain: Comparison with other orthopoxviruses [J].
Antoine, G ;
Scheiflinger, F ;
Dorner, F ;
Falkner, FG .
VIROLOGY, 1998, 244 (02) :365-396
[2]   Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein [J].
Belyakov, IM ;
Wyatt, LS ;
Ahlers, JD ;
Earl, P ;
Pendleton, CD ;
Kelsall, BL ;
Strober, W ;
Moss, B ;
Berzofsky, JA .
JOURNAL OF VIROLOGY, 1998, 72 (10) :8264-8272
[3]   Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza [J].
Bender, BS ;
Rowe, CA ;
Taylor, SF ;
Wyatt, LS ;
Moss, B ;
Small, PA .
JOURNAL OF VIROLOGY, 1996, 70 (09) :6418-6424
[4]   Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins:: implications for use as a human vaccine [J].
Blanchard, TJ ;
Alcamí, A ;
Andrea, P ;
Smith, GL .
JOURNAL OF GENERAL VIROLOGY, 1998, 79 :1159-1167
[5]   Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: Propagation and generation of recombinant viruses in a nonhuman mammalian cell line [J].
Carroll, MW ;
Moss, B .
VIROLOGY, 1997, 238 (02) :198-211
[6]   Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: A murine tumor model [J].
Carroll, MW ;
Overwijk, WW ;
Chamberlain, RS ;
Rosenberg, SA ;
Moss, B ;
Restifo, NP .
VACCINE, 1997, 15 (04) :387-394
[7]  
Collins P., 1996, FIELDS VIROLOGY, V1, P1313
[8]   RESPIRATORY SYNCYTIAL VIRUS (RSV) F-PROTEIN, G-PROTEIN, M2-PROTEIN (22K), AND N-PROTEINS EACH INDUCE RESISTANCE TO RSV CHALLENGE, BUT RESISTANCE INDUCED BY M2-PROTEINS AND N-PROTEINS IS RELATIVELY SHORT-LIVED [J].
CONNORS, M ;
COLLINS, PL ;
FIRESTONE, CY ;
MURPHY, BR .
JOURNAL OF VIROLOGY, 1991, 65 (03) :1634-1637
[9]   RESISTANCE TO RESPIRATORY SYNCYTIAL VIRUS (RSV) CHALLENGE INDUCED BY INFECTION WITH A VACCINIA VIRUS RECOMBINANT EXPRESSING THE RSV M2 PROTEIN (VAC-M2) IS MEDIATED BY CD8+ T-CELLS, WHILE THAT INDUCED BY VAC-F OR VAC-G RECOMBINANTS IS MEDIATED BY ANTIBODIES [J].
CONNORS, M ;
KULKARNI, AB ;
COLLINS, PL ;
FIRESTONE, CY ;
HOLMES, KL ;
MORSE, HC ;
MURPHY, BR .
JOURNAL OF VIROLOGY, 1992, 66 (02) :1277-1281
[10]   A COMPARISON IN CHIMPANZEES OF THE IMMUNOGENICITY AND EFFICACY OF LIVE ATTENUATED RESPIRATORY SYNCYTIAL VIRUS (RSV) TEMPERATURE-SENSITIVE MUTANT VACCINES AND VACCINIA VIRUS RECOMBINANTS THAT EXPRESS THE SURFACE GLYCOPROTEINS OF RSV [J].
CROWE, JE ;
COLLINS, PL ;
LONDON, WT ;
CHANOCK, RM ;
MURPHY, BR .
VACCINE, 1993, 11 (14) :1395-1404
1234